Trial design:
- Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic
acid-Irinotecan" or "HA-Irinotecan") regimen.
- Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
- Randomized 1:1, double-blinded, multi-centre, multi-national (Australia, Bulgaria,
Poland, Serbia, Russia, Ukraine and the United Kingdom).
- Dosing regimen:
- Irinotecan (180 mg/m2) or HA-Irinotecan (180 mg/m2), IV, over 90 minutes, day 1 (in
patients > 75 years of age, the irinotecan and HA-Irinotecan dose in must be
reduced to 150 mg/m2).
- Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with
irinotecan.
- 5-fluorouracil (5-FU), 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days
(total 2400 mg/m2 over 46-48 hours) continuous infusion.
- Repeat every 2 weeks for 8 months.
- Patient accrual over approximately 12-14 months.
- Monitoring to 18 months post-randomization.
- 390 patients.
- Progression Free Survival (PFS) primary endpoint.
- Safety analysis on the initial 20 patients.
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
Completed
Daiichi Sankyo Inc.
Phase 1/Phase 2
2012-07-01
This study is a Phase I/II trial of Tivantinib plus FOLFOX for the treatment of patients with
advanced solid tumors. In Phase I the Maximum Tolerated Dose (MTD) will be determined; in
Phase II patients with first-line metastatic GE cancer will be treated at the MTD. It is
hypothesized that the response rate (RR) will be improved from 45% to at least 65% under this
regimen.
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
Completed
Daiichi Sankyo, Inc.
Phase 1/Phase 2
2012-07-01
This study is a Phase I/II trial of Tivantinib plus FOLFOX for the treatment of patients with
advanced solid tumors. In Phase I the Maximum Tolerated Dose (MTD) will be determined; in
Phase II patients with first-line metastatic GE cancer will be treated at the MTD. It is
hypothesized that the response rate (RR) will be improved from 45% to at least 65% under this
regimen.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
